Wall Street analyst consensus regarding Nektar Therapeutics leans predominantly favorable, with a significant majority of covering research firms rating the equity as a buy. Supporters highlight ongoing clinical programs targeting autoimmune conditions and promising immunotherapy developments as long-term catalysts. Conversely, bearish voices point to negative earnings, future financing expectations, and distant clinical readouts as potential risk factors. Investors must carefully balance these contrasting clinical timelines and funding requirements against their personal risk appetite before trading.